Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
Want to see IN:LALPATHLAB full AI Analyst Report?
Top Page
Dr. Lal PathLabs Limited
(LALPATHLAB)
Select Model
Select Model
Rating:76Outperform
Price Target:
₹1,778.00
▲(20.71% Upside)
Action:Upgraded
Date:05/05/26
The score is driven primarily by strong financial performance (low leverage, solid cash generation, and steady growth), supported by constructive technical momentum. This is tempered by expensive valuation (high P/E and low yield) and signs of FY2026 margin pressure that warrant monitoring.
Positive Factors
Conservative balance sheet
A low debt-to-equity ratio (~0.08 in FY2026) and a meaningful reduction from ~0.25 in FY2023 provide lasting financial flexibility. This conservative leverage profile supports capex and network expansion, cushions downturns, lowers refinancing risk, and underpins long-term resilience.
Negative Factors
Margin compression risk
A sharp decline in gross margin and a dip in net margin in FY2026 point to structural cost or pricing pressures. If sustained, margin erosion will reduce operating leverage and cash available for reinvestment, weakening long-term profitability and returns unless addressed by cost or pricing actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A low debt-to-equity ratio (~0.08 in FY2026) and a meaningful reduction from ~0.25 in FY2023 provide lasting financial flexibility. This conservative leverage profile supports capex and network expansion, cushions downturns, lowers refinancing risk, and underpins long-term resilience.
Read all positive factors
Dr. Lal PathLabs Limited (LALPATHLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹279.63B
Dividend Yield0.89%
Average Volume (3M)3.61K
Price to Earnings (P/E)41.7
Beta (1Y)0.58
Revenue Growth12.25%
EPS Growth3.57%
CountryIN
Employees4,099
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)32.04
Shares Outstanding167,637,770
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio12.69
Price to Book (P/B)8.73
Price to Sales (P/S)7.93
P/FCF Ratio40.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)35.26
Revenue Forecast (FY)₹31.26B
Dr. Lal PathLabs Limited Business Overview & Revenue Model
Company Description
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopatho...
How the Company Makes Money
The company primarily makes money by charging fees for diagnostic testing services. Key revenue streams include: (1) Business-to-consumer (B2C) testing, where individual patients pay for pathology and diagnostic test packages (often via walk-ins, ...
Dr. Lal PathLabs Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.00B | 27.63B | 24.61B | 22.27B | 20.17B | 20.87B |
| Gross Profit | 15.59B | 11.61B | 16.38B | 14.62B | 12.87B | 15.85B |
| EBITDA | 8.43B | 7.83B | 7.89B | 6.78B | 5.32B | 6.13B |
| Net Income | 5.35B | 5.05B | 4.87B | 3.58B | 2.39B | 3.45B |
Balance Sheet | ||||||
| Total Assets | 29.59B | 31.46B | 27.17B | 24.56B | 23.86B | 23.53B |
| Cash, Cash Equivalents and Short-Term Investments | 13.02B | 13.32B | 11.65B | 9.43B | 8.14B | 6.82B |
| Total Debt | 2.55B | 1.99B | 1.57B | 2.47B | 4.20B | 5.32B |
| Total Liabilities | 5.37B | 6.05B | 5.10B | 5.71B | 6.86B | 8.10B |
| Stockholders Equity | 23.88B | 25.08B | 21.73B | 18.49B | 16.66B | 15.08B |
Cash Flow | ||||||
| Free Cash Flow | 1.90B | 5.35B | 5.25B | 4.84B | 4.11B | -294.49M |
| Operating Cash Flow | 3.24B | 7.02B | 5.69B | 5.35B | 4.56B | 4.47B |
| Investing Cash Flow | -3.88B | -4.88B | -3.03B | -242.69M | -2.87B | -4.49B |
| Financing Cash Flow | -1.13B | -2.63B | -3.34B | -4.14B | -2.83B | 1.36B |
Dr. Lal PathLabs Limited Technical Analysis
Positive
1472.95
Price Trends
1434.13
Positive
1426.07
Positive
1499.43
Positive
Market Momentum
68.23
Negative
65.13
Neutral
77.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LALPATHLAB, the sentiment is Positive. The current price of 1472.95 is below the 20-day moving average (MA) of 1541.97, above the 50-day MA of 1434.13, and below the 200-day MA of 1499.43, indicating a bullish trend. The MACD of 68.23 indicates Negative momentum. The RSI at 65.13 is Neutral, neither overbought nor oversold. The STOCH value of 77.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LALPATHLAB.
Dr. Lal PathLabs Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹279.63B | 41.73 | ― | 0.89% | 12.25% | 3.57% | |
73 Outperform | ₹75.51B | 34.04 | ― | 0.68% | 20.61% | 78.25% | |
72 Outperform | ₹107.45B | 44.11 | ― | 0.21% | 23.64% | 29.96% | |
72 Outperform | ₹20.07B | 21.88 | ― | 0.16% | 16.08% | 14.61% | |
71 Outperform | ₹130.36B | 52.62 | ― | 0.20% | 19.49% | 20.50% | |
58 Neutral | ₹18.25B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,668.05
262.12
18.64%
IN:KRSNAA
Krsnaa Diagnostics Limited
562.45
-76.01
-11.91%
IN:METROPOLIS
Metropolis Healthcare Ltd.
518.25
105.15
25.45%
IN:THYROCARE
Thyrocare Technologies Ltd
474.40
155.00
48.53%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,269.00
336.48
36.08%
IN:VIMTALABS
Vimta Labs Limited
449.35
-56.39
-11.15%
Dr. Lal PathLabs Limited Corporate Events
Dr. Lal PathLabs clears FY26 results, dividend and Dubai expansion as it acquires Shahbazkers Diagnostic Centre
Apr 30, 2026
Dr. Lal PathLabs’ board has approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 and recommended a final dividend of ₹4 per share, with a record date of 26 June 2026. The compa...
Dr. Lal PathLabs Confirms SEBI Depository Compliance for Q4 FY26
Apr 9, 2026
Dr. Lal PathLabs Limited has informed the Indian stock exchanges that its registrar and share transfer agent, MUFG Intime India Private Limited, has issued a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Par...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.